Chronic myelomonocytic leukemia (CMML-2)
Drug research and approvals for chronic myelomonocytic leukemia (CMML-2): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 4 studies of chronic myelomonocytic leukemia (CMML-2) are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, and FDA has 1 approved and 4 open orphan designations naming it.
- Recruiting worldwide: 4
- Trials authorized in Canada: 9
- FDA orphan approvals: 1
- EU medicines: 0
- A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)NCT06950034 · Phase 1 · Solu Therapeutics, Inc · starts Mar 13, 2025
- Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAMLNCT05584761 · Phase 1 / Phase 2 · The First Affiliated Hospital with Nanjing Medical University · starts Mar 1, 2022
- Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2,…NCT04771572 · Phase 1 · Newave Pharmaceutical Inc · starts May 8, 2022
- Combining Active and Passive DNA HypomethylationNCT03999723 · Phase 2 · Kirsten Grønbæk · starts Sep 11, 2019
Approved 2
- AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
- DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor
Phase 3 12 of 13
- CyclophosphamideDNA inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- BusulfanDNA inhibitor
- CytarabineDNA inhibitor
- Rigosertib
- DaunorubicinDNA topoisomerase II alpha inhibitor
- IdarubicinDNA topoisomerase II alpha inhibitor
- AldesleukinInterleukin-2 receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- ThioguanineInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- AsparaginaseAsparagine hydrolytic enzyme
Phase 2 10
- TacrolimusFK506-binding protein 1A inhibitor
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- ClofarabineRibonucleoside-diphosphate reductase RR1 inhibitor
- Fludarabine
- CobimetinibDual specificity mitogen-activated protein kinase kinase 1 inhibitor
- TipifarnibProtein farnesyltransferase inhibitor
- PevonedistatNEDD8 activating enzyme inhibitor
- Epoetin betaErythropoietin receptor agonist
Phase 1 or earlier 10
- PanobinostatHistone deacetylase inhibitor
- TagraxofuspInterleukin-3 receptor subunit alpha binding agent
- PacritinibTyrosine-protein kinase JAK2 inhibitor
- LintuzumabMyeloid cell surface antigen CD33 other
- VenetoclaxApoptosis regulator Bcl-2 inhibitor
- PrexasertibSerine/threonine-protein kinase Chk1 inhibitor
- LenzilumabGranulocyte-macrophage colony-stimulating factor inhibitor
- TamibaroteneRetinoic acid receptor beta agonist
- AlrizomadlinTumour suppressor p53/oncoprotein Mdm2 inhibitor
- CedazuridineCytidine deaminase inhibitor
How its trials ended
316 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 77 whose ending is known, 39% met their primary endpoint, 4% missed it and 57% stopped early.
- Completed, result not reported13041%
- Ongoing9931%
- Met its primary endpoint309%
- Stopped: other or unclear206%
- Status unknown103%
- Stopped: enrollment or feasibility72%
- Stopped: lack of efficacy62%
- Stopped: funding62%
- Stopped: sponsor or business decision52%
- Missed its primary endpoint31%
| Sep 7, 2023 | Protocol 10538, venetoclax in combination with ASTX727, an all-oral therapy for chronic myelomonocytic leukemia and other MDS/mpn with excess blasts…ASTX727 (cedazuridine-decitabine)/ Venetoclax | University Health Network | Ongoing |
| May 31, 2023 | A phase 1, open-label, multicenter, dose escalation study of PRT1419 injection as monotherapy or in combination with azacitidine or venetoclax in patients with…PRT1419 / Venetoclax / Azacitidine | Prelude Therapeutics | Closed |
| Jun 30, 2021 | A multiphase, pharmacokinetics, safety, and efficacy study of ASTX030 (azacitidine and cedazuridine) as monotherapy in subjects with myeloid neoplasm or in…Azacitidine-cedazuridine (ASTX030) / Azacitidine / Cedazuridine | Taiho Oncology | Ongoing |
| Jan 6, 2021 | Phase 1b/2 open-label, multicenter, dose optimization clinical study of the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of cfi…CFI-400945 | Treadwell Therapeutics, Inc. | Ongoing |
| Mar 6, 2020 | A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with…MBG453 | Novartis Pharmaceuticals | Closed |
| May 8, 2018 | An open-label, multicenter, extension study for subjects who participated in prior guadecitabine clinical studiesGuadecitabine (SGI-110) | Astex Pharmaceuticals Inc. | Closed |
| May 7, 2018 | A phase 3, randomized, controlled, open-label, clinical study of pevonedistat plus azacitidine versus single-agent azacitidine as first-line treatment for…Pevonedistat (MLN4924) / Azacitidine | Takeda Pharmaceuticals USA | Ongoing |
| Aug 18, 2016 | A phase 3, multicenter, randomized, open-label study of guadecitabine (SGI-110) versus treatment choice in adults with myelodysplastic syndromes (MDS) or…Guadecitabine (SGI-110) | Astex Pharmaceuticals Inc. | Closed |
| Feb 8, 2016 | A phase 2, randomized, controlled, open-label, clinical study of the efficacy and safety of pevonedistat plus azacitidine versus single-agent azacitidine in…Pevonedistat / Azacitidine | Takeda Pharmaceuticals USA | Closed |
| Jul 7, 2020 | InqoviIndicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and… | Astex Pharmaceuticals, Inc. | Approved |
| Oct 21, 2026 | OnvansertibTreatment of chronic myelomonocytic leukemia (CMML) | Cardiff Oncology Inc. | Designated |
| Feb 25, 2025 | Co-packaged combination of azacitidine and cedazuridineTreatment of chronic myelomonocytic leukemia (CMML) | Taiho Oncology, Inc. | Designated |
| Feb 8, 2024 | Recombinant, humanized immunoglobulin G1 monoclonal…Treatment of Chronic Myelomonocytic Leukemia | Immune-Onc Therapeutics | Designated |
| Nov 7, 2023 | Recombinant human signal regulating protein alpha…Treatment of chronic myelomonocytic leukemia | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA